Statements (55)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Basaglar
gptkb:Lantus |
gptkbp:activities |
provides a steady level of insulin
|
gptkbp:appointed_by |
subcutaneous injection
|
gptkbp:approves |
gptkb:2000
gptkb:FDA |
gptkbp:availability |
prescription only
|
gptkbp:brand |
gptkb:Basaglar
gptkb:Toujeo |
gptkbp:class |
long-acting insulin
|
gptkbp:clinical_trial |
studied for cardiovascular outcomes
studied for efficacy in glycemic control studied for long-term safety |
gptkbp:contraindication |
hypersensitivity to insulin glargine
|
gptkbp:developed_by |
gptkb:Sanofi
|
gptkbp:duration |
up to 24 hours
|
gptkbp:education |
storage instructions
recognizing hypoglycemia symptoms diet and exercise importance importance of blood glucose monitoring proper injection techniques |
gptkbp:financial_performance |
up to 28 days at room temperature
|
gptkbp:formulation |
solution for injection
|
https://www.w3.org/2000/01/rdf-schema#label |
insulin glargine
|
gptkbp:indication |
gptkb:Type_1_diabetes
Type 2 diabetes |
gptkbp:ingredients |
C267 H404 N72 O80 S6
|
gptkbp:interacts_with |
with beta-blockers
with corticosteroids with other antidiabetic medications with thiazolidinediones |
gptkbp:is_available_on |
vial
pre-filled pen |
gptkbp:is_used_for |
diabetes management
|
gptkbp:marketed_as |
gptkb:Lantus
|
gptkbp:pharmacokinetics |
slow absorption
insulin receptor agonist |
gptkbp:population |
gptkb:Person
adults |
gptkbp:premiered_on |
1 to 2 hours
|
gptkbp:previous_name |
gptkb:insulin_glargine
|
gptkbp:price |
varies by region
|
gptkbp:provides_information_on |
EASD guidelines
ADA Standards of Medical Care |
gptkbp:safety_features |
liver function assessment
monitoring for allergic reactions monitoring for injection site reactions regular Hb A1c testing renal function assessment |
gptkbp:side_effect |
weight gain
injection site reactions hypoglycemia |
gptkbp:storage |
refrigerated
|